Effect of Amifostine in Head and Neck Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Authors:
Open Access
- 2 May 2014
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (5) , e95968
Abstract
Amifostine is the most clinical used chemical radioprotector, but its effect in patients treated with radiation is not consistent. By searching Medline, CENTRAL, EMBASE, ASCO, ESMO, and CNKI databases, the published randomized controlled trials (RCTs) about the efficacy of amifostine in HNSCC patients treated with radiotherapy were collected. The pooled efficacy and side effects of this drug were calculated by RevMan software. Seventeen trials including a total of 1167 patients (604 and 563 each arm) were analyzed in the meta-analysis. The pooled data showed that the use of amifostine significantly reduce the risk of developing Grade3–4 mucositis (relative risk [RR],0.72; 95% confidence interval [CI],0.54–0.95; pp = 0.02), or late xerostomia (RR,0.60; 95%CI,0.49–0.74; pp = 0.03). However, subgroup analysis demonstrated that no statistically significant reduction of Grade3–4 mucositis (RR,0.97; 95% CI,0.74–1.26; p = 0.80), Grade 2–4 acute xerostomia (RR,0.35; 95%CI,0.02–5.44; p = 0.45), or late xerostomia (RR,0.40; 95%CI,0.13–1.24; p = 0.11) and Grade 3–4 dysphagia (RR,0.23; 95%CI,0.01–4.78; p = 0.35) was observed in patients treated with concomitant chemoradiotherapy. Compared with placebo or observation, amifostine does not show tumor protective effect in complete response (RR,1.02; 95%CI,0.89–1.17; p = 0.76) and partial response (RR,0.90; 95%CI, 0.56–1.44; p = 0.66). For the hematologic side effect, no statistical difference of Grade 3–4 leucopenia (RR,0.60; 95%CI,0.35–1.05; p = 0.07), anemia (RR,0.80; 95%CI, 0.42–1.53; p = 0.50) and thrombocytopenia (RR,0.43; 95%CI,0.16–1.15; p = 0.09) were found between amifostine and control groups. The most common amifostine related side effects were nausea, emesis, hypotension and allergic with an average incidence rate (Grade 3–4) of 5%, 6%, 4% and 4% respectively. This systematic review showed that amifostine significantly reduce the serious mucositis, acute/late xerastomia and dysphagia without protection of the tumor in HNSCC patients treated with radiotherapy. And the toxicities of amifostine were generally acceptable.Keywords
This publication has 43 references indexed in Scilit:
- Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled TrialsPLOS ONE, 2012
- Effect of Amifostine on Survival Among Patients Treated With Radiotherapy: A Meta-Analysis of Individual Patient DataJournal of Clinical Oncology, 2011
- Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancersPediatric Blood & Cancer, 2007
- Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinomaCancer, 2005
- Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostineEuropean Journal of Cancer, 2005
- The evaluation of amifostine for mucosal protection in patients with advanced loco-regional Squamous Cell Carcinomas of the Head and Neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily Radiotherapy (RT)Seminars in Oncology, 2004
- Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancerSeminars in Oncology, 2004
- A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparingSeminars in Oncology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986